IgG1 和 IgG4 在过敏原免疫疗法中作为主要 IgE 阻断抗体的作用

Q3 Medicine Allergo Journal International Pub Date : 2024-09-30 DOI:10.1007/s40629-024-00309-5

Barbara Bohle PhD

{"title":"IgG1 和 IgG4 在过敏原免疫疗法中作为主要 IgE 阻断抗体的作用","authors":"Barbara Bohle PhD","doi":"10.1007/s40629-024-00309-5","DOIUrl":null,"url":null,"abstract":"<p>Allergen immunotherapy (AIT) is the only treatment that modifies the allergic response to allergens. One immune mechanism associated with a reduction in clinical symptoms is the induction of immunoglobulin E (IgE)-blocking antibodies. In particular, AIT-induced allergen-specific IgG4 antibodies were regarded a candidate biomarker for clinical efficacy. With the knowledge that not all AIT-induced allergen-specific IgG antibodies bear blocking bioactivity, different in vitro assays became popular to assess the blocking capacity of sera collected during and after AIT. Their measuring principles vary in the detection of the prevention of IgE-binding to allergen or of allergen interactions with IgE bound to high-affinity Fc epsilon receptors on the surface of effector cells. More recently, the contribution to IgE-blocking of other isotypes that arise in the course of AIT, e.g., IgG1 and IgA, was confirmed. The results indicated that different isotypes of allergen-specific antibodies serve as dominant IgE-blocking factors in the course of AIT.</p>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"33 8","pages":"282 - 288"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The role of IgG1 and IgG4 as dominant IgE-blocking antibodies during allergen immunotherapy\",\"authors\":\"Barbara Bohle PhD\",\"doi\":\"10.1007/s40629-024-00309-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Allergen immunotherapy (AIT) is the only treatment that modifies the allergic response to allergens. One immune mechanism associated with a reduction in clinical symptoms is the induction of immunoglobulin E (IgE)-blocking antibodies. In particular, AIT-induced allergen-specific IgG4 antibodies were regarded a candidate biomarker for clinical efficacy. With the knowledge that not all AIT-induced allergen-specific IgG antibodies bear blocking bioactivity, different in vitro assays became popular to assess the blocking capacity of sera collected during and after AIT. Their measuring principles vary in the detection of the prevention of IgE-binding to allergen or of allergen interactions with IgE bound to high-affinity Fc epsilon receptors on the surface of effector cells. More recently, the contribution to IgE-blocking of other isotypes that arise in the course of AIT, e.g., IgG1 and IgA, was confirmed. The results indicated that different isotypes of allergen-specific antibodies serve as dominant IgE-blocking factors in the course of AIT.</p>\",\"PeriodicalId\":37457,\"journal\":{\"name\":\"Allergo Journal International\",\"volume\":\"33 8\",\"pages\":\"282 - 288\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Allergo Journal International\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://link.springer.com/article/10.1007/s40629-024-00309-5\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergo Journal International","FirstCategoryId":"1085","ListUrlMain":"https://link.springer.com/article/10.1007/s40629-024-00309-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

过敏原免疫疗法（AIT）是唯一能改变对过敏原过敏反应的治疗方法。与临床症状减轻相关的一种免疫机制是诱导免疫球蛋白 E（IgE）阻断抗体。其中，AIT 诱导的过敏原特异性 IgG4 抗体被认为是临床疗效的候选生物标志物。由于知道并非所有 AIT 诱导的过敏原特异性 IgG 抗体都具有阻断生物活性，因此流行采用不同的体外检测方法来评估 AIT 期间和之后收集的血清的阻断能力。它们的测量原理各不相同，都是检测是否阻止了 IgE 与过敏原的结合或过敏原与效应细胞表面高亲和力 Fc epsilon 受体结合的 IgE 的相互作用。最近，在 AIT 过程中出现的其他异型（如 IgG1 和 IgA）对 IgE 阻断作用的贡献也得到了证实。结果表明，过敏原特异性抗体的不同异型是 AIT 过程中的主要 IgE 阻断因子。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

The role of IgG1 and IgG4 as dominant IgE-blocking antibodies during allergen immunotherapy

Allergen immunotherapy (AIT) is the only treatment that modifies the allergic response to allergens. One immune mechanism associated with a reduction in clinical symptoms is the induction of immunoglobulin E (IgE)-blocking antibodies. In particular, AIT-induced allergen-specific IgG4 antibodies were regarded a candidate biomarker for clinical efficacy. With the knowledge that not all AIT-induced allergen-specific IgG antibodies bear blocking bioactivity, different in vitro assays became popular to assess the blocking capacity of sera collected during and after AIT. Their measuring principles vary in the detection of the prevention of IgE-binding to allergen or of allergen interactions with IgE bound to high-affinity Fc epsilon receptors on the surface of effector cells. More recently, the contribution to IgE-blocking of other isotypes that arise in the course of AIT, e.g., IgG1 and IgA, was confirmed. The results indicated that different isotypes of allergen-specific antibodies serve as dominant IgE-blocking factors in the course of AIT.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Allergo Journal International Medicine-Immunology and Allergy

CiteScore

4.60

自引率

0.00%

发文量

期刊介绍： Allergo Journal International is the official Journal of the German Society for Applied Allergology (AeDA) and the Austrian Society for Allergology and Immunology (ÖGAI). The journal is a forum for the communication and exchange of ideas concerning the various aspects of allergy (including related fields such as clinical immunology and environmental medicine) and promotes German allergy research in an international context. The aim of Allergo Journal International is to provide state of the art information for all medical and scientific disciplines that deal with allergic, immunological and environmental diseases. Allergo Journal International publishes original articles, reviews, short communications, case reports, and letters to the editor. The articles cover topics such as allergic, immunological and environmental diseases, the latest developments in diagnosis and therapy as well as current research work concerning antigens and allergens and aspects related to occupational and environmental medicine. In addition, it publishes clinical guidelines and position papers approved by expert panels of the German, Austrian and Swiss Allergy Societies. All submissions are reviewed in single-blind fashion by at least two reviewers. Originally, the journal started as a German journal called Allergo Journal back in 1992. Throughout the years, English articles amounted to a considerable portion in Allergo Journal. This was one of the reasons to extract the scientific content and publish it in a separate journal. Hence, Allergo Journal International was born and now is the international continuation of the original German journal. Nowadays, all original content is published in Allergo Journal International first. Later, selected manuscripts will be translated and published in German and included in Allergo Journal.

期刊最新文献

Requirements for regulatory acceptance of biomarkers Impact of obesity on allergic respiratory diseases and on mental and cognitive performance One health: the impact of environment, detergents and hygiene on barrier, microbiome and allergy Discharge management after anaphylaxis The role of IgG1 and IgG4 as dominant IgE-blocking antibodies during allergen immunotherapy